

Decline & Fall of Informed Consent

Long Live Shared Decision
Making with Certified
Patient Decision Aids

2

Thaddeus Pope

I have **no** relevant financial relationships with any ineligible companies.

I will **not** discuss off label use or investigational use.

.





5 6











research

Treatment


11 12

moving to same approach for treatment

informed consent







roadmap



19

3 parts

design flaws IC

22

failures of IC

new paradigm


23

21

design flaws



25



disclosure not understanding

28

27






29 30





32





34



MIRANDA WARNING

. YOU HAVE THE RIGHT TO REMAIN SILENT.

. ANYTHING YOU SAY CAN AND WILL BE USED AGAINST YOU IN A COURT OF LAW.

YOU HAVE THE RIGHT TO TALK TO A LAWYER AND HAVE HIM PRESENT WITH YOU WHILE YOU ARE BEING QUESTIONED.

"do you understand each of these rights?"

37

disclosure
not
understanding

38

39



40

disclosure
not
understanding

worse

41 42



less Pt centered


44

46

disclose even less

not what
reasonable
patient would
want/need


what **clinicians** decide to disclose



47

8





50

some states extra low

51

failures
informed consent

52

only duty disclose RBA 2 failures

53 54

does not happen

when happens done badly

56

few examples

1

58

Medscape

2020 survey1400 physicians


would you withhold risks from patient to encourage consent?

59

60

10

55









how **frequent** was discussion of risks & benefits?

9%

65 66

inadequate 91% disclosure



67





70

how **frequent** was discussion of risks & benefits?



71 72







how frequent was discussion of risks & benefits?

76





process measure

worse

79

80

outcome measure

even if disclosed, did patient understand?

81

82



most are seriously misinformed

83

few examples

1

85

The role of informed consent in patient complaints: Reducing hidden health system costs and improving patient engagement through shared decision making

By Karen L. Posner, PhD, Julie Severson, PhD, JD, and Karen B. Domino, MD, MPH



87

89

88

86

"potential risk of harm . . . included"

"nerve injury
. . . disclosed"

90



"not clearly understood"

92

"not understand . . . manifest as pain or weakness in an extremity"

94

The NEW ENGLAND JOURNAL of MEDICINE

93

Patients' Expectations about Effects of Chemotherapy for Advanced Cancer


chemotherapy for incurable cancers – palliative only

no chance


chemotherapy will cure them

95 96

11/6/2024







similar findings across clinical settings

99 100





101 102

RBA not disclosed



103


new paradigm

mandated SDM w/ PDA

105

106





107 108





evidence based educational tools 112

111

present options clearly & graphically

209 RCT 110,000 114

113



Screening for Lung
Cancer with Low
Dose Computed
Tomography

116





117

before CT scan

"must receive
... SDM visit"

119 120

"include ...
one or more
decision aids"

why require PDA?

122

121

doubt

accurate
unbiased
balanced from the clinician

123 124



your discussion
with patient is
not good enough

125 126


patient must


also get informed

with PDA





127





129 130





131 132


"formal SDM interaction"

"evidence-based decision tool"

134

133





old



137





140



141

FDA Strengthens Safety Requirements and Updates Study Results for Breast Implants

Agency adds restrictions and approves new labeling for all approved breast implants



142

SENATE, No. 3375

STATE OF NEW JERSEY

218th LEGISLATURE

conclusion

143 144





146



value concordant care too important to leave solely in hands of clinicians

147 148



Thaddeus Mason Pope, JD, PhD, HEC-C

Mitchell Hamline School of Law 875 Summit Avenue Saint Paul, Minnesota 55105

T 651-695-7661

C 310-270-3618

150

E Thaddeus.Pope@mitchellhamline.edu

W www.thaddeuspope.com

B medicalfutility.blogspot.com